Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transient receptor potential cation channel subfamily M member 1 (TRPM1) is a non-selective cation channel that plays a fundamental role in the mammalian visual system (UniProt, 2023). It is the primary effector channel in retinal ON-bipolar cells, where it is coupled to the metabotropic glutamate receptor 6 (mGluR6) signaling cascade (Morgans et al., 2009). In the dark, glutamate released by photoreceptors binds to mGluR6, keeping TRPM1 channels closed; light reduces glutamate release, leading to the opening of TRPM1 and subsequent cell depolarization. Mutations in TRPM1 are a major cause of complete congenital stationary night blindness (cCSNB), a condition where the retina fails to transmit signals from photoreceptors to the inner retina (van Genderen et al., 2009). In the context of optogenetics, TRPM1 is a key target for vision restoration therapies aimed at bypassing lost photoreceptors in diseases like retinitis pigmentosa (Cehajic-Kapetanovic et al., 2015). These strategies involve using viral vectors to express light-sensitive proteins that can either directly activate TRPM1 or act as a light-gated version of the channel itself within surviving retinal neurons. By re-establishing light-sensitive cation influx in the ON-pathway, these therapies aim to restore functional visual signals to the brain. Additionally, TRPM1 serves as a diagnostic biomarker in oncology, as its expression is frequently downregulated during the progression of malignant melanoma (Duncan et al., 1998).
The mechanism involves the restoration of light-sensitive cation conductance in retinal ON-bipolar cells. In gene therapy for CSNB, wild-type TRPM1 is delivered to restore the endogenous mGluR6 signaling pathway (van Genderen et al., 2009). In optogenetic applications, engineered light-gated channels or chimeric proteins (e.g., Opto-mGluR6) are expressed to trigger TRPM1-mediated depolarization or mimic its function in response to light, thereby bypassing dysfunctional photoreceptors and restoring visual signaling (Cehajic-Kapetanovic et al., 2015).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transient receptor potential cation channel subfamily M member 1 (TRPM1) (TRPM1).